<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165955</url>
  </required_header>
  <id_info>
    <org_study_id>KX-ORAX-007</org_study_id>
    <secondary_id>U1111-1176-4228</secondary_id>
    <nct_id>NCT03165955</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients</brief_title>
  <official_title>A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athenex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaEssentia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Athenex, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-arm PK study in patients for whom paclitaxel
      treatment is indicated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer
      patients for whom paclitaxel treatment is indicated. The study contains 3 periods: the
      Screening / Baseline Period, the Treatment Period, and the Follow-up Period. A Final Visit
      will occur within 7 days of the last dose of study treatment. If subjects achieve stable
      disease (SD), partial response (PR), or complete response (CR) at the end of the Treatment
      Period, they may continue Oraxol treatment in a separate extension study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Actual">November 22, 2018</completion_date>
  <primary_completion_date type="Actual">November 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_AUC (0-52)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the mean, SD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_Cmax</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the mean, SD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_Ctrough(24)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the mean, SD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_Ctrough(48)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the mean, SD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_Cmax(0-24)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the mean, SD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_Cmax(24-48)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the mean, SD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_Cmax(48-52)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the mean, SD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_tmax(0-24)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the median, minimum, maximum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_tmax(24-48)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the median, minimum, maximum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for paclitaxel_tmax(48-52)</measure>
    <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
    <description>PK parameters were summarized using the median, minimum, maximum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Oraxol in Breast Cancer Patients</measure>
    <time_frame>From enrollment through study completion, approximately 17 weeks</time_frame>
    <description>Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>From baseline through study completion, around 21 weeks</time_frame>
    <description>Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From baseline through study completion, around 21 weeks</time_frame>
    <description>PFS and OS were analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From baseline through study completion, around 21 weeks</time_frame>
    <description>PFS and OS were analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Breastcancer</condition>
  <arm_group>
    <arm_group_label>Oraxol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oraxol</intervention_name>
    <description>HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules</description>
    <arm_group_label>Oraxol</arm_group_label>
    <other_name>HM30181 methanesulfonate monohydrate</other_name>
    <other_name>Oral paclitaxel capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. Women ≥18 years of age on day of consent

          3. Breast cancer in patients for whom treatment with IV paclitaxel at 80 mg/m2 as
             monotherapy has been recommended by their oncologist

          4. Measurable disease as per RECIST v1.1 criteria

          5. Adequate hematological status as demonstrated by not requiring transfusion support or
             granulocyte-colony stimulating factor (G-CSF) maintain:

               -  Absolute neutrophil count (ANC) ≥1.5 x 10^9/L

               -  Platelet count ≥100 x 10^9/L

               -  Hemoglobin (Hgb) ≥9 g/dL

          6. Adequate liver function

               -  Total bilirubin of ≤1.5 mg/dL

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x upper
                  limit of normal (ULN) or ≤5 x ULN if liver metastasis is present

               -  Alkaline phosphatase (ALP) ≤3 x ULN or ≤5 x ULN if bone metastasis is present

               -  Gamma glutamyl transferase (GGT) &lt;10 x ULN

          7. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          9. Life expectancy of at least 3 months

         10. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all
             treatment days

         11. Willing to abstain from alcohol consumption for 3 days before the first dose of study
             drug through the completion of the second inpatient PK sampling period

         12. Willing to refrain from caffeine consumption for 12 hours before each inpatient dosing
             period through the completion of protocol-specified PK sampling for that week

         13. Subjects must be postmenopausal (&gt;12 months without menses) or surgically sterile (ie,
             by hysterectomy and/or bilateral oophorectomy) or must be using effective
             contraception (ie, oral contraceptives, intrauterine device, double barrier method of
             condom and spermicide) and agree to continue use of contraception for 30 days after
             their last dose of assigned study treatment.

         14. Subjects who are of childbearing potential must have a negative serum pregnancy test
             at Screening and within 96 hours before dosing.

        Exclusion Criteria:

          1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or
             previous investigational products (IPs)

          2. If previously treated with a taxane (paclitaxel or docetaxel) as part of
             anthracycline-based adjuvant chemotherapy or for metastatic disease, the subject
             relapsed less than 1 year following treatment

          3. Subjects unable to swallow study medication in its intact form or have clinically
             significant malabsorption syndrome

          4. Only site of metastatic disease is unmeasurable according to RECIST v1.1 criteria

          5. Known CNS metastasis, including leptomeningeal involvement

          6. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever
             is longer

          7. Are currently receiving other medications intended for the treatment of their
             malignancy

          8. Women who are pregnant or breastfeeding

          9. Taking prohibited medications:

         10. Use of warfarin. Subjects receiving warfarin who are otherwise eligible and who may be
             appropriately managed with low molecular weight heparin, in the opinion of the
             Investigator, may be enrolled in the study provided they are switched to low molecular
             weight heparin at least 7 days prior to receiving study treatment.

         11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, myocardial infarction within the last
             6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease
             requiring oxygen, known bleeding disorders, or any concomitant illness or social
             situation that would limit compliance with study requirements

         12. Known allergic reaction or intolerance to study medication components

         13. Known allergic reaction or intolerance to contrast media

         14. Subjects who, in the Investigator's opinion, are not suitable for participation in
             this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsu-Yi Chao, MD, DMS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University Shuang Ho Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans Generla Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shuang Ho Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 14, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <results_first_submitted>May 14, 2020</results_first_submitted>
  <results_first_submitted_qc>June 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2020</results_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03165955/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03165955/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 31 subjects were screened; 3 subjects were screen failures and were not included in the analysis</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
          <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening/Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 31 subjects were screened; 3 subjects were screen failures and were not included in the analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
          <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_AUC (0-52)</title>
        <description>PK parameters were summarized using the mean, SD</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_AUC (0-52)</title>
          <description>PK parameters were summarized using the mean, SD</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3419" spread="1475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3224" spread="1150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_Cmax</title>
        <description>PK parameters were summarized using the mean, SD</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_Cmax</title>
          <description>PK parameters were summarized using the mean, SD</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366" spread="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356" spread="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_Ctrough(24)</title>
        <description>PK parameters were summarized using the mean, SD</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_Ctrough(24)</title>
          <description>PK parameters were summarized using the mean, SD</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_Ctrough(48)</title>
        <description>PK parameters were summarized using the mean, SD</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_Ctrough(48)</title>
          <description>PK parameters were summarized using the mean, SD</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_Cmax(0-24)</title>
        <description>PK parameters were summarized using the mean, SD</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_Cmax(0-24)</title>
          <description>PK parameters were summarized using the mean, SD</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_Cmax(24-48)</title>
        <description>PK parameters were summarized using the mean, SD</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_Cmax(24-48)</title>
          <description>PK parameters were summarized using the mean, SD</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274" spread="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_Cmax(48-52)</title>
        <description>PK parameters were summarized using the mean, SD</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_Cmax(48-52)</title>
          <description>PK parameters were summarized using the mean, SD</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" spread="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288" spread="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_tmax(0-24)</title>
        <description>PK parameters were summarized using the median, minimum, maximum</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_tmax(0-24)</title>
          <description>PK parameters were summarized using the median, minimum, maximum</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.97" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.93" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_tmax(24-48)</title>
        <description>PK parameters were summarized using the median, minimum, maximum</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_tmax(24-48)</title>
          <description>PK parameters were summarized using the median, minimum, maximum</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.03" lower_limit="24.47" upper_limit="27.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" lower_limit="22.78" upper_limit="27.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for paclitaxel_tmax(48-52)</title>
        <description>PK parameters were summarized using the median, minimum, maximum</description>
        <time_frame>Week 1 (Days 1,2, 3) and Week 4 (Days 1,2,3)</time_frame>
        <population>Twenty-five subjects completed 2-period PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for paclitaxel_tmax(48-52)</title>
          <description>PK parameters were summarized using the median, minimum, maximum</description>
          <population>Twenty-five subjects completed 2-period PK assessment.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.02" lower_limit="48.22" upper_limit="51.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.03" lower_limit="47.05" upper_limit="51.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Oraxol in Breast Cancer Patients</title>
        <description>Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs).</description>
        <time_frame>From enrollment through study completion, approximately 17 weeks</time_frame>
        <population>Safety Analysis Population included all subjects who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Oraxol in Breast Cancer Patients</title>
          <description>Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs).</description>
          <population>Safety Analysis Population included all subjects who received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with At Least One TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to dose interruption or reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to study drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation from the study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE related to Oraxol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE related to progression of disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE with action taken for other treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with At Least One Grade ≥3 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC.</description>
        <time_frame>From baseline through study completion, around 21 weeks</time_frame>
        <population>The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 post treatment tumor response evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC.</description>
          <population>The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 post treatment tumor response evaluation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigator Assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-evaluable (NE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICRRC Assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-evaluable (NE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>PFS and OS were analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation</description>
        <time_frame>From baseline through study completion, around 21 weeks</time_frame>
        <population>The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 post treatment tumor response evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>PFS and OS were analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation</description>
          <population>The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 post treatment tumor response evaluation.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigator Assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICRRC Assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.86" lower_limit="15.00" upper_limit="NA">not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>PFS and OS were analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation</description>
        <time_frame>From baseline through study completion, around 21 weeks</time_frame>
        <population>The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 post treatment tumor response evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
            <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>PFS and OS were analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation</description>
          <population>The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 post treatment tumor response evaluation.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigator Assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICRRC Assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>An AE was any untoward medical occurrence in a subject or clinical investigation subject, and included events occurring from the time a subject signed the ICF through the last subject contact. The period is up to 21 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oraxol (Oral Paclitaxel Plus HM30181)</title>
          <description>Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regional Project Manager</name_or_title>
      <organization>Athenex Inc.</organization>
      <phone>+886-978365735</phone>
      <email>lmeiying@athenex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

